InvestorsHub Logo
Followers 105
Posts 16351
Boards Moderated 0
Alias Born 06/24/2014

Re: None

Monday, 04/15/2024 8:10:26 AM

Monday, April 15, 2024 8:10:26 AM

Post# of 10487
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONVO News